Study directory

ADHD studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
1740studies shown
Showing 1,393-1,404 of 1,740
Drug study icon
CompletedNCT00796302

Treatment of Severe Childhood Aggression (The TOSCA Study)

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Stony Brook
Why is this study shown?

This study is directly about ADHD.

ADHDDrugA study involving a medication or substance.From 6 Years to 12 Years
Countries
United States
Sponsor
Michael Aman
Condition
ADHD
Other study type icon
Not recruitingISRCTN82596506

The Incredible Years Ireland study

This study is looking at whether 1 can help people with Hyperkinetic disorders, Mental and Behavioural Disorders, or Attention deficit hyperactivity disorder. Participants take part in 1 and complete follow-up assessments.

In Ireland
Why is this study shown?

This study is directly about ADHD.

ADHDOtherFrom 3 Years to 6 Years
Countries
Ireland
Sponsor
Archways Ltd (Ireland)
Condition
ADHD
Device study icon
Not recruitingISRCTN93932965

Understanding sensory experiences of neurodiverse adolescents in mainstream secondary schools

This public ISRCTN record appears to relate to adhd. HopeStage keeps this listing available so people can review the official source, understand the basic study status, and decide what questions to ask before contacting the research team.

In United Kingdom
Why is this study shown?

This study is directly about ADHD.

ADHDOtherFrom 10 Years to 19 Years
Countries
United Kingdom
Sponsor
Sheffield Hallam University
Condition
ADHD
Drug study icon
CompletedEUCTR 2011-000210-19

A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
Belgium, Denmark, Germany, ...
Sponsor
Novartis Pharma Services AG
Condition
ADHD
Drug study icon
CompletedEUCTR 2005-003002-28

A 7 week multicenter, double-blind, randomized, placebo-controlled cross-over evaluation of the efficacy and safety of a modified-release oral dosage form of methylphenidate-HCl, Ritalin LA® (20 mg...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
Germany
Sponsor
Novartis Pharma GmbH
Condition
ADHD
Drug study icon
CompletedEUCTR 2007-002111-82

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
France, United Kingdom, Belgium, ...
Sponsor
Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium
Condition
ADHD
Drug study icon
CompletedEUCTR 2004-000730-37

A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose-response phase III A study to evaluate safety and efficacy of Prolonged Release (PR) OROS methylphenidate (18, 36 a...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
Czechia, Denmark, Finland, ...
Sponsor
Janssen-Cilag Medical Affairs EMEA
Condition
ADHD
Drug study icon
CompletedEUCTR 2009-011745-94

A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel-group Study to Compare the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
France, United Kingdom, Belgium, ...
Sponsor
Shire Pharmaceutical Development Limited
Condition
ADHD
Drug study icon
CompletedEUCTR 2008-000720-10

A Phase III, Double- Blind, Placebo- Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with A...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
France, United Kingdom, Belgium, ...
Sponsor
Shire Pharmaceutical Development Limited
Condition
ADHD
Drug study icon
CompletedEUCTR 2008-000679-90

A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and ...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
France, United Kingdom, Belgium, ...
Sponsor
Shire Pharmaceutical Development Limited
Condition
ADHD
Drug study icon
CompletedEUCTR 2004-004088-31

A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 weeks in Newly Diagnosed Children and Adolescents Outpatients with Attention-Deficit/Hyp...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Spain
Why is this study shown?

This study is directly about ADHD.

ADHDDrug
Countries
Spain
Sponsor
Lilly S.A.
Condition
ADHD
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.